The combination of red palm oil and rooibos show anti-inflammatory effects in rats

Journal of Inflammation (United Kingdom)

Volumn 11, Issue 1, 2014, Pages

  Katengua Thamahane, Emma ^a   Marnewick, Jeanine L ^a   Ajuwon, Olawale R ^b   Chegou, Novel N ^b   Szücs, Gergö ^c   Ferdinandy, Péter ^c,d   Csont, Tamás ^c   Csonka, Csaba ^c   Van Rooyen, Jacques ^a  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF SZEGED   (Hungary)

^d PHARMAHUNGARY GROUP   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; RED PALM OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE MODEL; HEART; HEART FUNCTION; HEART PROTECTION; HERBAL TEA; INFLAMMATION; ISOLATED HEART; MALE; NONHUMAN; RAT; TISSUE LEVEL; WISTAR RAT;

EID: 84988311365     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/s12950-014-0041-4     Document Type: Article

References (95)

1. Halliwell B: Free radicals and antioxidants-quo vadis? Trends Pharmacol Sci 2011, 32(3):125-130.
2. Pantsi WG, Marnewick JL, Esterhuyse AJ, Rautenbach F, Van Rooyen J: Rooibos (Aspalathus linearis) offers cardiac protection against ischaemia/ reperfusion in the isolated perfused rat heart. Phytomedicine 2011, 18:1220-1228.
3. Esterhuyse AJ, van Rooyen J, Strijdom H, Bester D, du Toit EF: Proposed mechanisms for red palm oil induced cardioprotection in a model of hyperlipidaemia in the rat. Prostaglandins Leukot Essent Fatty Acids 2006, 75:375-384.
4. Engelbrecht AM, Esterhuyse AJ, du Toit EF, Lochner A, van Rooyen J: p38-MAPK and PKB/Akt, possible role players in red palm oil-induced protection of the isolated perfused rat heart? J Nutr Biochem 2006, 17(4):265-271.
5. Engelbrecht AM, Odendaal L, du Toit EF, Kupai K, Tamás C, Ferdinandy P, van Rooyen J: "The effect of dietary red palm oil on the functional recovery of the ischaemic/reperfused isolated rat heart: the involvement of the PI3-Kinase signaling pathway. Lipids Health Dis 2009, 8:1-8.
6. van Rooyen J, Esterhuyse AJ, Engelbrecht AM, du Toit EF: Health benefits of a natural carotenoid rich oil: a proposed mechanism of protection against ischaemia/reperfusion injury. Asia Pac J Clin Nutr 2008, 17(S1):316-319.
7. Bester DJ, Kupai K, Csont T, Szucs G, Csonka C, Esterhuyse AJ, Ferdinandy P, Van Rooyen J: Dietary red palm oil supplementation reduces myocardial infarct size in an isolated perfused rat heart model. Lipids Health Dis 2010, 9(64):1-9.
8. Bacová Barbara J, Viczenczová C, Knezl V, Dosenko V, Benova T, Navarová J, Gonçalvesová E, van Rooyen J, Weismann P, Slezák J, Narcis T: Upregulation of myocardial connexin-43 in spontaneously hypertensive rats fed red palm oil is most likely implicated in its ant-arrhythimic effects. Can J Physio Phamarcol 2012, 90:1235-1245.
9. Ajuwon OR, Katengua-Thamahane E, Van Rooyen J, Oguntibeju O, Marnewick JL: Protective Effects of Rooibos (Aspalathus linearis) and/or Red Palm Oil (Elaeis guineensis) Supplementation on tert-Butyl Hydroperoxide-Induced Oxidative Hepatotoxicity in Wistar Rats. Evid-Based Compl Alt 2013, 2013:984273.
10. Hariharan K, Purushothama S, Raina PL: Studies on the red palm oil: Effect of partial supplementation of saturated fats upon lipids and lipoproteins. Nutr Res 1996, 16(8):1381-1392.
11. Kritchevsky D, Tepper SA, Kuksis A, Wright S, Czarnecki SK SK: Cholesterol Vehicle in experimental Atherosclerosis. 22. Refined, Bleached, Deodorized (RBD) Palm oil, Randomized palm oil and red palm oil. Nutr Res 2000, 20(6):887-892.
12. Nagendran B, Unnithan UR, Choo YM, Sundram K: Characteristics of red palm oil, a carotene-and vitamin E-rich refined oil for food uses. Food Nutr Bull 2000, 21(2):189-194.
13. Sundram K, Sambanthamurthi R, Tan Y: Palm fruit chemistry and nutrition. Asia Pacific J Clin Nutr 2003, 12(3):355-362.
14. Sambanthamurthi R, Sundram K, Tan YA: Chemistry and biochemistry of palm oil. Prog Lipid Res 2000, 39(6):507-558.
15. Packer L, Weber SU, Rimbach G: Molecular aspects of a-tocotrienol antioxidant action and cell signalling. J Nutr 2001, 131:369S-373S.
16. Theriault A, Chao JT, Wang Q, Gapor A, Adeli K: Tocotrienol; A review of its therapeutic potential. Clin Biochem 1999, 32:309-319.
17. Sen CK, Rink C, Khanna S: Palm oil-derived natural vitamin E alpha tocotrienol in brain health and disease. J Am Coll Nutr 2010, 29:S314-S323.
18. Aggarwal BB, Sundaram C, Prasad R: Kannappan. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol 2010, 80:1613-1631.
19. Jiang Q, Elson-Schwab I, Courtemanche Ames BNC: γ-Tocopherol and its major metabolite, in contrast to a-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 2000, 97(21):11494-11499.
20. Theriault A, Chao JT, Gapor A: Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to Monocytes. Atherosclerosis 2002, 160:21-23.
21. Jiang Q, Ames BN: γ-Tocopherol, but not a-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 2003, 17:816-822.
22. Noguchi N, Hanyu R, Nonaka A, Okimoto Y, Kodama T: Inhibition of THP-1 cell adhesion to endothelial cell by a-tocopherol and a-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radic Biol Med 2003, 34(12):1614-1620.
23. McKay DL, Blumberg JB: Review of the bioactivity of south african herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytother Res 2007, 21:1-16.
24. Joubert E, Gelderblom WCA, Louw A, de Beer D: South African herbal teas: Aspalathus linearis. Cyclopia spp. and Athrixia Phylicoides-A review. J Ethnopharmacol 2008, 119:376-412.
25. Marnewick JL: Rooibos and honeybush: recent advances in chemistry, biological activity and pharmacognosy. In African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality, ACS symposium series 1021. Edited by Juliana HR, Simon JE, Ho C-T. Oxford, United Kingdom: Oxford University Press; 2009:277-294.
26. Duthie GG, Gardner PT, Kyle JAM: Plant polyphenols: are they the new magic bullet? Proc Nutr Soc 2003, 62:599-603.
27. Joubert E, Winterton P, Britz TJ, Ferreira D: Superoxide anion and a; a-diphenyl-b-picrylhydrazyl radical scavenging capacity of rooibos (Aspalathus linearis) aqueous extracts, crude phenolic fractions, tannin and flavonoids. Food Res Int 2004, 37:133-138.
28. Liu CM, Zheng YL, Lu J, Zhang ZF, Fan SH, Wu DM, Ma JQ: Quercetin protects rat liver against lead-induced oxidative stress and apoptosis. Environ Toxicol Pharmacol 2010, 29:158-166.
29. Nikolova V, Petrova S, Petkova V, Pavlova S, Michailova A, Georgieva T: Antioxidant effects of rooibos tea on workers occupationally exposed to lead. Toxicol Lett 2007, 172:S120-S121.
30. Kawano A, Nakamura H, Hata S, Minakawa M, Miura Y, Yagasaki K: Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16:437-443.
31. Schulz H, Joubert E, Schütze W: Quantification of quality parameters for reliable evaluation of green rooibos (Aspalathus linearis). Eur Food Res Technol 2003, 216:539-543.
32. Marnewick JL, Joubert E, Joseph S, Swanevelder S, Swart P, Gelderblom W: Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas. Cancer Lett 2005, 224:193-202.
33. Baba H, Ohtsuka Y, Haruna H, Lee T, Nagata S, Maeda M, Yamashiro Y, Shimizu T: Studies of anti-inflammatory effects of Rooibos tea in rats. Pediatr Int 2009, 51:700-704.
34. Villaño D, Pecorari M, Testa MF, Raguzzini A, Stalmach A, Crozier A, Tubili C, Serafini M: Unfermented and fermented rooibos teas (Aspalathus linearis) increase plasma total antioxidant capacity in healthy humans. Food Chem 2010, 123:679-683.
35. Persson IAL, Persson K, Hägg S, Anderson RGG: Effects of green tea, black tea and rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Publ Health Nutr 2010, 13(5):730-737.
36. Persson IAL: The pharmacological mechanism of angiotensin-converting enzyme inhibition by green tea, rooibos and enalaprilat-a study on enzyme kinetics. Phytother Res 2012, 26:517-521.
37. Marnewick JL, Rautenbach F, Venter I, Neethling H, Blackhurst DM, Wolmarans P, Macharia M: Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for cardiovascular disease. J Ethnopharmacol 2011, 133:46-52.
38. Petrova A, Davids LM, Rautenbach F, Marnewick JL: Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice. J. Photochem Photobiol B 2011, 103:126-139.
39. Ulicná O, Vancova O, Božek P, Cársky J, Sebeková K, Boor P, Nakano M, Greksák M: Rooibos tea (Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats. Physiol Res 2006, 55:157-164.
40. Joubert E: HPLC quantification of the dihydrochalcones, aspalathin and nothofagin in rooibos tea (Aspalathus linearis) as affected by processing. Food Chem 1996, 55(4):40-11.
41. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-II10.
42. Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83:456S-460S.
43. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741.
44. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
45. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999, 26(12):2562-2571.
46. Callow AD: Cardiovascular disease 2005-the global picture. Vasc Pharmacol 2006, 45(5):302-307.
47. Haines DD, Varga B, Bak I, Juhasz B, Mahmoud FF, Kalantari H, Gesztelyi R, Lekli I, Czompa A, Tosaki A: Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in suppression of respiratory infl ammation: a comparison with ibuprofen. Phytother Res 2011, 25:128-136.
48. Delgado J, del Pilar TM, Garrido M, Barriga C, Paredes SD, Espino J, Rodríguez AB: Systemic Inflammatory load in young and old ringdoves is modulated by consumption of a Jerte Valley Cherry-Based Product. J Med Food 2012, 15(8):707-712.
49. Zhou Z, Nair MG, Claycombe KJ: Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin. Phytomedicine 2012, 19:878-881.
50. Mahmoud FF, Al-Awadhi R, Haines DD, Dashti A, Dashti H, Al-Ozairi E, Bak I, Tosaki A: Sour Cherry Seed Kernel Extract increases Heme Oxygenase-1 expression and decreases representation of CD3+ TNF-a + and CD3+ IL-8+ subpopulations in peripheral blood leukocyte cultures from Type 2 Diabetes patients. Phytother Res 2013, 27:767-774.
51. Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komal M: Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem 2006, 70(4):926-932.
52. Du J, An J, Wei N, Guan T, Pritchard KA Jr, Shi Y: Increased resistance to LPS-induced myocardial dysfunction in the Brown Norway Rats versus Dahl S Rats: Role of inflammatory cytokines and nuclear factor kB pathway. Shock 2010, 33(3):332-336.
53. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997, 9:4-9.
54. Zeuke S, Ulmerb AJ, Kusumoto S, Katus HA, Heine H: TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002, 56:126-134.
55. Kelly RA, Smith TW: Cytokines and cardiac contractile function. Circulation 1997, 95:778-781.
56. Marnewick JL, Joubert E, Swart P, Der Westhuizen FV, Gelderblom WC: Modulation of hepatic drug metabolizing enzymes and oxidative status by rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), green and black (Camellia sinensis) teas in rats. J Agricult Food Chem 2003, 51(27):8113-8119.
57. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 71:248-254.
58. Kadokami T, Mctiernan CF, Kubota T, Frye CS, Bounoutas GS, Robbins PD, Watkins SC, Feldman AM: Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 2001, 280:H2281-H2291.
59. Gruys E, Toussaint MJM, Niewold T, Koopmans SJ: Acute phase reaction and acute phase proteins. Zhejiang Univ SCI 2005, 6B(11):1045-1056.
60. Fearon WF, Fearon DT: Inflammation and cardiovascular disease; role of the interleukin-1 receptor antagonist. Circulation 2008, 117:2577-2579.
61. Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999, 189(4):615-625.
62. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999, 104:271-280.
63. Wright SD: Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999, 189(4):605-609.
64. Akira S: Toll-like receptor signaling. J Biol Chem 2003, 278(40):38105-38108.
65. Sweet MJ, Hume DA: Endotoxin signal transduction in macrophages. J Leukoc Biol 1996, 60(1):8-26.
66. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W: Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 2008, 295:H1311-H1318.
67. Chao W: Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 2009, 296:H1-H12.
68. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, Liu P: Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999, 99:1492-1498.
69. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992, 215:356-362.
70. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK: IL-6 enhances plasma IL-1ra, IL-10, cortisol in humans. Am J Physiol Endocrinol Metab 2003, 285:E433-E437.
71. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320.
72. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 1(83):113-118.
73. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A: IL6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4:551-556.
74. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143-3150.
75. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis & Rheum 2004, 50(6):1761-1769.
76. Rennick DM, Fort MM, Davidson NJ: Studies with IL-10-/- mice: an overview. J Leukoc Biol 1997, 61:389-396.
77. Heumann D, Galley P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, Glauser MP, Baumgartner JD: Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992, 148:3505-3512.
78. Rabe C, Steenkamp JA, Joubert E, Burger JFW, Ferrema D: Phenolic metabolites from rooibos tea (Aspalathus Linearis). Phytochemistry 1994, 35(6):1559-1565.
79. Rotelli AE, Guardia T, Juárez AO, de la Rocha NE, Pelzer LE: Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res 2003, 48:601-606.
80. Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ: Distinctive antioxidant and anti-inflammatory effects of flavonols. J Agric Food Chem 2006, 54:9798-9804.
81. Crouvezier S, Powell B, Keir D, Yaqoob P: The effects of phenolic components of tea on the production of pro-and anti-inflammatory cytokines by human leukocytes in vitro. Cytokine 2001, 13:280-286.
82. Kim HP, Kun HS, Chang HW, Kang SS: Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci 2004, 96:229-245.
83. Comalada M, Ballester I, Bailon E, Sierra S, Xaus J, Gálvez J, de Medina FS, Zarzuelo A: Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem Pharmacol 2006, 72:1010-1021.
84. Mutalib MSA, Khaza'ai H, Wahle KWJ: Palm-tocotrienol rich fraction (TRF) is a more effective inhibitor of LDL oxidation and endothelial cell lipid peroxidation than a-tocopherol in vitro. Food Res Int 2003, 36:405-413.
85. Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants. Nutrition 1996, 12:274-277.
86. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24:816-823.
87. Jones SP, Trocha SD, Lefer DJ: Cardioprotective actions of endogenous IL-10 are independent of iNOS. Am J Physiol Heart Circ Physiol 2001, 281:H48-H52.
88. Yang Z, Zingarelli B, Szabo C: Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 2000, 101:1019-1026.
89. Rietschel ET, Brade H: Bacterial endotoxins. Sci Am 1992, 267:53-61.
90. Wang YP, Sato C, Mizoguchi K, Yamashita Y, Maeta MOH: Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc Res 2002, 56:33-42.
91. Yao YW, Zhang GH, Zhang YY, Li WD, Wang CH, Yin CY, Zhang FM: Lipopolysaccharide pretreatment protects against ischemia/reperfusion injury via increase of HSP70 and inhibition of NF-κB. Cell Stress Chaperon 2011, 16:287-296.
92. Lew WYW, Bayna E, Molle ED, Dalton ND, Lai NC, Bhargava V, Mendiola V, Clopton P, Tang T: Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS One 2013, 8(4):e61057.
93. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, Gao X: Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biosoc Sci 2009, 16(74):1-11.
94. Lastres-Becker I, Molina-Holgado FJ: Endotoxin preconditioning protects neurons from in vitro ischemia: role of endogenous IL-1beta and TNF-alpha. J Neuroimmunol 2006, 173:108-116.
95. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP: Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab 2007, 27(10):1663-1674.